Examkin

All practice questions

4736 questions

All types4,736Multiple choice2,413Multiple select567Numeric127Matching858Ordering771
Question 4361Question →

A 62-year-old man comes to the clinic reporting severe, generalized itching that typically occurs immediately after taking a warm shower. He also notes intermittent headaches and a "fullness" in his head over the past three months. His medical history includes hypertension. He has a 30-pack-year smoking history but quit 10 years ago. His current medications include lisinopril. Blood pressure is 155/92 mmHg, and pulse is 82/min. Physical examination reveals a plethoric appearance of the face and a spleen tip palpable 3 cm below the left costal margin. Laboratory studies show:

Laboratory ParameterResultReference Range
Hemoglobin19.5 g/dL19.5 \text{ g/dL}13.5−17.5 g/dL13.5-17.5 \text{ g/dL}
Hematocrit59%59\%41−53%41-53\%
Leukocyte count14,500/mm314,500/\text{mm}^34,500−11,000/mm34,500-11,000/\text{mm}^3
Platelet count550,000/mm3550,000/\text{mm}^3150,000−400,000/mm3150,000-400,000/\text{mm}^3
Serum erythropoietin2 mU/mL2 \text{ mU/mL}4−26 mU/mL4-26 \text{ mU/mL}
Arterial oxygen saturation (room air)96%96\%≥95%\ge 95\%

Which of the following best explains this patient's laboratory profile?

Show answer & explanation

Answer: Constitutive activation of a non-receptor tyrosine kinase

Answer

Constitutive activation of a non-receptor tyrosine kinase
The patient's clinical presentation (aquagenic pruritus, splenomegaly, plethora) and laboratory findings (panmyelosis with an elevated hematocrit, leukocytes, and platelets) are classic for polycythemia vera (PV). The critical distinguishing laboratory value is the suppressed serum erythropoietin (EPO) level. In PV, a primary myeloproliferative neoplasm, red blood cell production is autonomous and independent of EPO. This autonomous production leads to increased oxygen delivery, which exerts negative feedback on the kidneys, suppressing endogenous EPO synthesis. Over 95% of PV cases are caused by a V617F point mutation in the JAK2 gene. The JAK2 gene encodes a non-receptor tyrosine kinase that normally mediates intracellular signaling downstream of the EPO receptor. The mutation results in constitutive, ligand-independent activation of this kinase, driving unchecked myeloid proliferation.

Step-by-Step Solution

1
Analyze the hematologic parameters.
The patient has elevated hemoglobin, hematocrit, leukocytes, and platelets, indicating panmyelosis (hyperproliferation of all three myeloid lineages).
Identifying panmyelosis narrows the differential diagnosis toward a primary bone marrow disorder rather than an isolated red blood cell issue.
2
Evaluate the serum erythropoietin (EPO) level in the context of the elevated hematocrit.
The serum EPO level is suppressed (low).
A low EPO level differentiates primary polycythemia (EPO-independent red blood cell production) from secondary polycythemia (where EPO is appropriately or autonomously elevated).
3
Correlate the laboratory findings and clinical presentation with the underlying pathophysiology.
The combination of panmyelosis, low EPO, aquagenic pruritus, and splenomegaly confirms Polycythemia Vera, which is driven by a JAK2 mutation (a non-receptor tyrosine kinase).
Understanding the molecular mechanism of the confirmed diagnosis is necessary to identify the correct answer choice.

Key Concept

Polycythemia vera is a primary myeloproliferative neoplasm characterized by panmyelosis and a suppressed erythropoietin level, predominantly driven by a constitutively active JAK2 mutation.
Question 4362Question →

Match each of the following clinical investigation objectives with the epidemiological study design that is optimally suited to address it.

Click a left item, then click its matching right item

Items

Determining the current prevalence of unrecognized chronic kidney disease within a specific metropolitan area during a single calendar year.
Identifying potential past environmental exposures associated with the development of an exceedingly rare, newly identified neurodegenerative disorder.
Measuring the 15-year incidence of hepatocellular carcinoma by enrolling healthy volunteers, classifying them by baseline alcohol consumption, and tracking their outcomes.
Evaluating whether a novel biologic agent is clinically superior to standard-of-care therapy for maintaining remission in patients with moderate-to-severe Crohn disease.

Matches

Show answer & explanation

Answer

The correct pairings are: prevalence determination with cross-sectional study, rare disease etiology with case-control study, long-term incidence measurement with prospective cohort study, and therapeutic efficacy evaluation with randomized controlled trial.
Each study design is optimally matched to its distinct methodological strength. Cross-sectional studies provide prevalence data. Case-control studies are highly efficient for rare diseases because they secure a sufficient number of cases upfront. Prospective cohort studies are best for establishing incidence and temporal relationships between exposure and disease. Randomized controlled trials minimize confounding to definitively assess treatment efficacy.

Step-by-Step Solution

1
Analyze the temporal direction and primary goal of each research scenario.
Identified whether the study looks forward in time, backward in time, acts at a single point, or involves active intervention.
Temporal direction and investigator involvement are the primary differentiating factors between major epidemiological study designs.
2
Match the prevalence scenario.
Paired the single calendar year prevalence study with the cross-sectional design.
Cross-sectional studies are a 'snapshot' in time used to measure prevalence.
3
Match the rare disease scenario.
Paired the rare neurodegenerative disorder investigation with the case-control design.
Rare outcomes require case-control designs to ensure enough statistical power without needing massive, unfeasible sample sizes.
4
Match the incidence scenario.
Paired the 15-year tracking of healthy volunteers based on alcohol use with the prospective cohort design.
Tracking exposure groups forward in time to measure new disease development defines a prospective cohort.
5
Match the therapeutic comparison scenario.
Paired the biologic agent versus standard care evaluation with the randomized controlled trial.
Testing a novel therapeutic agent's superiority requires an experimental design with randomization to control for confounding variables.

Key Concept

Selection of epidemiological study designs based on research objectives, disease rarity, and temporal relationships.
Estimated Time:1m 30s
Question 4363Question →

A hospital infection control committee is evaluating a new ultraviolet (UV) room disinfection protocol to reduce the incidence of hospital-acquired *Clostridioides difficile* infections. A crossover trial is conducted across four medical wards. Because the new protocol requires significant capital investment and additional staffing, the hospital administration insists on highly rigorous evidence before adopting the technology hospital-wide. To ensure this, the investigators set the predetermined significance level (α\alpha) at 0.010.01 rather than the conventional 0.050.05. The overall duration of the study and the total number of patient admissions monitored will remain exactly as originally planned. Which of the following is the most likely statistical consequence of applying this more stringent significance threshold?

Show answer & explanation

Answer: Increased probability of failing to identify a true reduction in infection rates

Answer

Setting a more stringent significance level (α=0.01\alpha = 0.01) decreases statistical power, which corresponds to an increased probability of committing a Type II error (failing to identify a true reduction in infection rates).
The significance level (α\alpha) represents the probability of committing a Type I error, which is rejecting a true null hypothesis. By lowering α\alpha from 0.050.05 to 0.010.01, the investigators make the criteria for statistical significance more stringent, thereby reducing the risk of a false-positive conclusion. However, α\alpha and β\beta (the probability of a Type II error) are inversely related when the sample size is fixed. A Type II error occurs when a study fails to reject a false null hypothesis (a false negative). Therefore, decreasing α\alpha inevitably increases β\beta, which directly translates to an increased probability of failing to identify a true reduction in infection rates. Because statistical power is defined as 1−β1 - \beta, the overall power of the study decreases.

Step-by-Step Solution

1
Identify the proposed methodological change in the trial design.
The significance threshold (α\alpha) is tightened from 0.050.05 to 0.010.01 while maintaining the same fixed sample size and study duration.
To isolate which statistical parameters are directly affected by this specific adjustment.
2
Analyze the direct relationship between α\alpha and Type I error.
A lower α\alpha directly reduces the probability of committing a Type I error (a false positive conclusion).
The α\alpha level explicitly defines the maximum acceptable Type I error rate established before the study begins.
3
Determine the downstream effect on Type II error (β\beta) and statistical power.
Because α\alpha and β\beta are inversely related for a fixed sample size, lowering α\alpha inevitably increases β\beta.
Shifting the critical value to be more stringent makes it mathematically harder to reject the null hypothesis, thereby increasing the chance of missing a true clinical effect (a Type II error).

Key Concept

In a study with a fixed sample size, there is an inverse relationship between the probability of a Type I error (α\alpha) and a Type II error (β\beta). Decreasing α\alpha increases β\beta, which consequently decreases the statistical power (1−β1 - \beta) of the study.
Question 4364Question →

Seeking to establish care, a 38-year-old woman arrives at the ambulatory clinic for a comprehensive wellness evaluation. She was diagnosed with systemic lupus erythematosus (SLE) complicated by class III lupus nephritis five years ago. Her disease has been clinically quiescent for the past three years on a maintenance regimen of mycophenolate mofetil and 10 mg of daily prednisone. She feels well and has no new symptoms. Her husband accompanies her, and she notes they have been mutually monogamous for the past decade.

Review of her preventive health records reveals the following:
* Dual-energy x-ray absorptiometry (DEXA) scan performed 6 months ago showed normal bone mineral density.
* Following her SLE diagnosis, she completed three consecutive normal annual cervical cytology exams. Her most recent screening, performed 2 years ago, was a negative cervical cytology with a negative high-risk HPV co-test.
* She received the 20-valent pneumococcal conjugate vaccine (PCV20) 1 year ago.
* She received the inactivated quadrivalent influenza vaccine 3 weeks ago at a community health fair.

Based on current immunization and screening guidelines, which of the following is the most appropriate next step in preventive care for this patient?

Show answer & explanation

Answer: Administer the recombinant zoster vaccine

Answer

Administer the recombinant zoster vaccine
The Advisory Committee on Immunization Practices (ACIP) recommends two doses of the recombinant zoster vaccine (RZV) for adults aged 19 years and older who are or will be immunodeficient or immunosuppressed due to disease or therapy. This patient's ongoing maintenance immunosuppression with mycophenolate mofetil and prednisone places her at high risk for herpes zoster reactivation. Therefore, administering the recombinant zoster vaccine is the most appropriate next step in her preventive care.

Step-by-Step Solution

1
Assess the patient's immune status and comorbidities.
The patient has systemic lupus erythematosus and is actively taking mycophenolate mofetil and prednisone, classifying her as significantly immunocompromised.
Immunocompromised status fundamentally alters the standard age cutoffs and intervals for both vaccinations and cancer screenings.
2
Evaluate vaccine indications based on age and immune status.
While routine zoster vaccination begins at age 50, the recombinant zoster vaccine is specifically indicated for immunocompromised adults aged 19 years and older. She requires this vaccine.
Immunosuppression places her at high risk for herpes zoster reactivation.
3
Rule out contraindicated interventions.
The live-attenuated varicella vaccine is absolutely contraindicated due to her active use of antimetabolite therapy (mycophenolate).
Live vaccines pose a risk of disseminated infection in severely immunocompromised hosts.
4
Evaluate the current status of age- and risk-appropriate cancer screening and other vaccines.
Cervical co-testing is on a 3-year interval for immunosuppressed patients and is not due. PCV20 provides complete pneumococcal coverage without needing PPSV23. Mammography does not begin until age 40.
Ensures no other competing guideline takes priority or is currently due.

Key Concept

Preventive Care Guidelines in Immunocompromised Adults
Question 4365Question →

A multidisciplinary team at an academic medical center is designing a prospective, randomized, double-blind, placebo-controlled trial to evaluate a new targeted biologic therapy for refractory ulcerative colitis. The primary endpoint is the rate of clinical remission at 5252 weeks. The trial is designed with a two-sided alpha level of 0.050.05. A pre-study statistical analysis determines that enrolling 280280 patients per arm will provide a 90%90\% probability of detecting a true absolute difference in clinical remission rates of 15%15\% or greater between the active drug and placebo.

If the actual difference in remission rates between the biologic and placebo is indeed 15%15\%, what is the probability (expressed as a percentage) that the trial will incorrectly fail to demonstrate a statistically significant difference between the two groups?

Show answer & explanation

Answer: 10

Answer

10
The scenario describes a study with a statistical power of 90%90\%. Power is defined as the probability of correctly rejecting the null hypothesis when there is a true difference (i.e., avoiding a Type II error). The question asks for the probability of failing to detect a true difference, which is the exact definition of a Type II error (β\beta). Since Power=1−β\text{Power} = 1 - \beta, the Type II error rate is calculated as 1−0.90=0.101 - 0.90 = 0.10, which is 10%10\%.

Step-by-Step Solution

1
Define statistical power in the context of the described study.
The statistical power is given as 90%90\%.
Power is explicitly defined in the stem as the 90%90\% probability of detecting a true absolute difference between the active drug and placebo.
2
Identify what statistical metric the question is asking to find.
The question asks for the probability of incorrectly failing to demonstrate a difference when a true difference exists.
This specific scenario defines a false-negative result, which corresponds to the Type II error rate (β\beta).
3
Calculate the Type II error (β\beta) from the given statistical power.
β=100%−90%=10%\beta = 100\% - 90\% = 10\%.
Statistical power and Type II error are mathematically complementary probabilities (1−β=Power1 - \beta = \text{Power}).

Key Concept

Statistical power (1−β1 - \beta) and Type II error (β\beta) are complementary probabilities. A Type II error occurs when a study incorrectly fails to reject a false null hypothesis.
Question 4366Question →

A 6565-year-old patient in the intensive care unit is being evaluated for new-onset bleeding. 1010 days ago, the patient underwent an emergency laparotomy for a perforated viscus and has since been kept strictly nil per os (NPO) due to a prolonged postoperative ileus. The patient's management includes intravenous hydration, parenteral nutrition, and broad-spectrum intravenous antibiotics. Today, the nursing staff notes continuous blood oozing from venipuncture sites and the development of large ecchymoses on the bilateral upper extremities.

Laboratory studies are obtained and reveal the following:

Laboratory ParameterResultReference Range
Platelet count185,000/mm3185,000/\text{mm}^3150,000–400,000/mm3150,000\text{--}400,000/\text{mm}^3
Prothrombin time (PT)26 seconds26\text{ seconds}11–15 seconds11\text{--}15\text{ seconds}
Activated partial thromboplastin time (aPTT)54 seconds54\text{ seconds}25–40 seconds25\text{--}40\text{ seconds}
Fibrinogen320 mg/dL320\text{ mg/dL}150–400 mg/dL150\text{--}400\text{ mg/dL}
D-dimer0.35 \mug/mL FEU0.35\text{ \mu g/mL FEU}<0.50 \mug/mL FEU<0.50\text{ \mu g/mL FEU}
Aspartate aminotransferase (AST)34 U/L34\text{ U/L}10–40 U/L10\text{--}40\text{ U/L}
Alanine aminotransferase (ALT)41 U/L41\text{ U/L}7–56 U/L7\text{--}56\text{ U/L}

Which of the following is the most likely pathophysiologic mechanism responsible for these laboratory findings?

Show answer & explanation

Answer: Eradication of normal enteric microbial flora

Answer

Eradication of normal enteric microbial flora
The correct answer identifies the eradication of normal enteric microbial flora. Vitamin K is a fat-soluble vitamin essential for the gamma-carboxylation of coagulation factors II, VII, IX, and X, as well as proteins C and S. Humans rely on two sources of vitamin K: dietary intake (primarily green leafy vegetables) and synthesis by normal intestinal flora. This patient has been NPO (lacking dietary intake) and on broad-spectrum antibiotics (eradicating gut flora) for 10 days, which perfectly aligns with the time required to deplete hepatic vitamin K stores (typically 7-10 days). Deficiency first prolongs the PT (due to the short half-life of Factor VII) and subsequently prolongs the aPTT. Crucially, the lack of vitamin K does not affect platelet production, fibrinogen synthesis, or cause fibrinolysis, explaining the normal platelet count, fibrinogen, and D-dimer.

Step-by-Step Solution

1
Analyze the patient's clinical history and risk factors.
The patient has been NPO and on broad-spectrum antibiotics for 10 days.
Identifying these risk factors points toward nutritional deficiencies, particularly vitamin K, which is synthesized by intestinal flora and requires dietary fat for absorption.
2
Interpret the provided coagulation panel.
PT and aPTT are significantly prolonged, while platelet count, fibrinogen, and D-dimer are entirely normal.
This specific pattern differentiates isolated factor deficiencies from consumptive processes. A normal platelet count and D-dimer effectively rule out disseminated intravascular coagulation (DIC).
3
Synthesize the laboratory findings with the clinical history to determine the underlying mechanism.
The combined prolongation of PT and aPTT reflects deficiencies in factors II, VII, IX, and X, which rely on vitamin K. The mechanism is the depletion of vitamin K-producing gut bacteria due to antibiotics, exacerbated by a lack of enteral vitamin K intake.
Body stores of vitamin K are small and can be depleted in 7-10 days, making this the classic presentation of hospital-acquired vitamin K deficiency.

Key Concept

Patients who are strictly NPO and receiving prolonged broad-spectrum antibiotics are at high risk for vitamin K deficiency, which presents with prolonged PT and aPTT but normal platelet counts, fibrinogen, and D-dimer levels.
Question 4367Question →

A 31-year-old G2P1 woman at 28 weeks gestation presents to the clinic for a routine prenatal visit. Her pregnancy has been uncomplicated to date. Her medical history is significant for mild intermittent asthma, which is well-controlled with an albuterol inhaler as needed. She feels well and reports normal fetal movement. Her blood type is AB-positive. Review of her immunization records shows that she received a complete series of standard childhood vaccines. She also received a tetanus-diphtheria-acellular pertussis (Tdap) vaccine two years ago during the third trimester of her first pregnancy. An inactivated influenza vaccine was administered three weeks ago. Vital signs and physical examination are unremarkable. Fundal height is 28 cm, and the fetal heart rate is 145/min. Which of the following is the most appropriate preventive intervention for this patient at today's visit?

Show answer & explanation

Answer: Administration of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine

Answer

Administration of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine
The administration of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine is the most appropriate intervention. The Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists (ACOG) strongly recommend that all pregnant women receive a Tdap vaccine during every pregnancy, optimally between 27 and 36 weeks of gestation. This recommendation applies regardless of the interval since the patient's last Tdap vaccination. The rationale is to maximize the maternal antibody response, which facilitates the passive transplacental transfer of IgG antibodies to the fetus. This provides the newborn with critical protection against pertussis (whooping cough) during the vulnerable first few months of life before they are old enough to receive their own primary DTaP series.

Step-by-Step Solution

1
Analyze the patient's gestational age and current risk profile.
The patient is at 28 weeks gestation, has a positive Rh blood type, and has a history of a Tdap vaccine 2 years ago.
Gestational age and prior medical history dictate the specific timing of routine prenatal preventive interventions.
2
Evaluate the indication for the Tdap vaccine.
Tdap is required.
Current guidelines mandate a Tdap booster during every single pregnancy (ideally between 27 and 36 weeks) to provide the fetus with passive immunity against pertussis, regardless of how recently the mother received a prior dose.
3
Rule out the other presented interventions based on timing or contraindications.
Anti-D is unnecessary (Rh-positive); GBS screening is premature (done at 36-37 weeks); MMR is contraindicated (live vaccine); PCV20 is deferred in pregnancy.
Ensures the selected intervention is the singular correct choice for today's visit without conflicting with other guidelines.

Key Concept

Maternal Immunization Guidelines
Estimated Time:1m 15s
Question 4368Question →

A state health department is planning a pragmatic clinical trial to evaluate a new smartphone-based behavioral intervention for patients with poorly controlled type 2 diabetes. The primary outcome will be the absolute change in hemoglobin A1c (HbA1c) after 6 months. The investigators initially aimed to achieve 80% power to detect a 0.6% difference in HbA1c between the intervention and standard care groups, utilizing a two-sided alpha of 0.05. During the planning phase, budget constraints necessitate a 20% reduction in the maximum allowable sample size.

To compensate for this loss of sample size, which of the following methodological adjustments would increase the statistical power of the study? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Implement stricter inclusion criteria to create a more clinically homogenous study cohort; Redesign the intervention to target a patient subset in which the expected mean difference in HbA1c between groups is larger

Answer

Implementing stricter inclusion criteria to create a more clinically homogenous study cohort, and redesigning the intervention to target a patient subset in which the expected mean difference is larger.
Statistical power (the probability of correctly rejecting a false null hypothesis) is determined by four main factors: sample size, effect size, significance level (alpha), and the variance (standard deviation) of the outcome in the population. When budget constraints force a reduction in sample size, power decreases. To compensate, investigators must alter one of the other three parameters. Implementing stricter inclusion criteria makes the cohort more homogenous, which reduces the variance (spread) of the data. Lower variance narrows the standard error and increases power. Redesigning the intervention to target a subset with a larger expected difference increases the expected effect size. A larger effect size means the distribution curve of the alternative hypothesis is shifted further away from the null hypothesis curve, making a true difference easier to detect (increased power).

Step-by-Step Solution

1
Identify the primary relationship between sample size and statistical power.
A reduction in sample size directly decreases the statistical power of the study.
Smaller sample sizes lead to wider standard errors, making it more difficult to detect a true difference between groups.
2
Determine which variables can be manipulated to increase statistical power to offset the smaller sample size.
Statistical power can be increased by increasing the effect size, increasing the alpha level, or decreasing the population variance.
Power is a mathematical function of sample size, effect size, variance, and the predetermined significance level (alpha).
3
Evaluate each option based on its effect on power.
Increasing population homogeneity decreases variance (increases power). Increasing the expected difference increases effect size (increases power).
These adjustments mathematically narrow the distribution curves and shift them further apart, respectively, leading to a higher probability of correctly rejecting the null hypothesis.

Key Concept

Statistical power is directly proportional to sample size, effect size, and alpha level, and inversely proportional to population variance.
Question 4369Question →

A 34-year-old healthcare worker is evaluated during a routine employee health examination. He has no significant past medical history and takes no medications. He reports feeling well, with no history of fatigue, jaundice, abdominal pain, or recent acute illnesses. Vital signs are within normal limits. Physical examination reveals no hepatosplenomegaly, scleral icterus, or stigmata of chronic liver disease. The results of his laboratory workup are shown below:

TestResultReference Range
Alanine aminotransferase (ALT)22 U/L10 - 40 U/L
Aspartate aminotransferase (AST)20 U/L10 - 40 U/L
Total bilirubin0.8 mg/dL0.1 - 1.2 mg/dL
Hepatitis B surface antigen (HBsAg)PositiveNegative
Hepatitis B surface antibody (Anti-HBs)NegativePositive
Hepatitis B core antibody, IgM (Anti-HBc IgM)NegativeNegative
Hepatitis B core antibody, IgG (Anti-HBc IgG)PositiveNegative
Hepatitis B e antigen (HBeAg)NegativeNegative
Hepatitis B e antibody (Anti-HBe)PositiveNegative
HBV DNA450 IU/mLNot detected

Based on these findings, which of the following is the most accurate diagnostic interpretation?

Show answer & explanation

Answer: Inactive chronic hepatitis B infection

Answer

Inactive chronic hepatitis B infection
The correct answer is inactive chronic hepatitis B infection. This patient has positive HBsAg with a positive Anti-HBc IgG and negative Anti-HBc IgM, which establishes a diagnosis of chronic Hepatitis B infection. Furthermore, he is HBeAg-negative and Anti-HBe-positive, which generally correlates with lower viral infectivity. The diagnosis of an inactive chronic carrier state is definitively confirmed by the low viral load (HBV DNA < 2,000 IU/mL) and normal liver transaminases (ALT and AST), indicating an absence of active viral replication and active hepatic inflammation.

Step-by-Step Solution

1
Evaluate the Hepatitis B surface antigen (HBsAg) status.
HBsAg is positive.
Presence of HBsAg indicates an ongoing Hepatitis B infection, ruling out a resolved infection or immunity from vaccination.
2
Differentiate between an acute and a chronic infection.
Anti-HBc IgM is negative, but Anti-HBc IgG is positive.
The absence of IgM and the presence of IgG against the core antigen confirms that the infection is chronic (lasting longer than 6 months).
3
Assess the level of viral replication and hepatic inflammation.
HBeAg is negative, Anti-HBe is positive, HBV DNA is low (450 IU/mL), and transaminases (ALT/AST) are within normal limits.
This specific combination indicates an inactive carrier state with minimal viral replication and no active liver damage, differentiating it from chronic active hepatitis.

Key Concept

Interpretation of Hepatitis B serological profiles to classify disease state (e.g., active vs. inactive chronic infection).
Estimated Time:1m 0s
Question 4370Question →

An ambulatory care physician is evaluating a 58-year-old male who was diagnosed with primary hypertension and hyperlipidemia six months ago. At that time, he was prescribed lisinopril and atorvastatin. Today, his blood pressure is 156/94 mmHg. When asked about his daily medication routine, the patient admits he has not filled the prescriptions. He states, 'I feel completely fine, and my brother told me those cholesterol pills will destroy my liver. I prefer to let my body handle things naturally.'

Which of the following is the most appropriate initial response by the physician?

Show answer & explanation

Answer: Tell me more about your specific concerns regarding how these medications might affect your liver.

Answer

The most appropriate initial response is to ask the patient to elaborate on his specific concerns about the medications and his liver.
The correct approach uses an open-ended statement to explore the patient's health beliefs and fears. In motivational interviewing and patient-centered counseling, understanding the patient's perspective is a prerequisite to providing effective education. By asking the patient to elaborate on his brother's advice and his fears of liver damage, the physician validates the patient's concerns, builds trust, and gathers the necessary information to eventually provide targeted, reassuring education regarding the actual safety profile of the prescribed medications.

Step-by-Step Solution

1
Identify the primary clinical issue from the vignette.
The patient is exhibiting medication non-adherence due to a lack of symptoms and externally influenced fears about medication toxicity.
Understanding the root cause of non-adherence dictates the counseling strategy.
2
Determine the optimal communication framework for this scenario.
The physician must use a patient-centered, motivational interviewing approach to explore health beliefs before offering medical facts or alternatives.
Direct contradiction or paternalistic lecturing usually increases patient defensiveness and reinforces non-adherence.
3
Select the response that best matches this framework.
The response asking the patient to 'tell me more' directly addresses his stated fear and encourages dialogue.
Open-ended questions build the therapeutic alliance and provide the physician with context needed to properly educate the patient later in the visit.

Key Concept

Patient-Centered Communication and Medication Adherence
Question 4371Question →

A primary care physician is managing a full schedule of adult patients presenting for health maintenance visits. Based on current United States Preventive Services Task Force (USPSTF) and Advisory Committee on Immunization Practices (ACIP) guidelines, match each patient's clinical vignette with the most appropriate next step in preventive care.

Click a left item, then click its matching right item

Items

Despite meeting the age and pack-year criteria for lung cancer screening, this 58-year-old oxygen-dependent man with severe COPD has explicitly refused any future thoracic surgeries. He recently received his annual influenza and pneumococcal vaccines.
Presenting for a routine wellness exam, a 42-year-old healthy woman seeks advice on cancer prevention. She has no significant family history. Her last primary HPV test was normal two years ago, and her adult immunizations are up to date.
A 53-year-old healthy man is seen for a routine physical. He is a lifelong nonsmoker with no chronic conditions. Records show a normal screening colonoscopy performed at age 45, and he received Tdap and influenza vaccines earlier this week.
Having undergone a total hysterectomy for symptomatic uterine fibroids at age 45, this 66-year-old woman is establishing care. She is up to date on her pneumococcal vaccination (received at 65) and had a normal mammogram last month.

Matches

Show answer & explanation

Answer

Match the 58-year-old man refusing surgery with omitting LDCT. Match the 42-year-old woman with initiating screening mammography. Match the 53-year-old healthy man with administering a pneumococcal conjugate vaccine. Match the 66-year-old woman with prior benign total hysterectomy with discontinuing cervical cancer screening.
Each patient's clinical scenario aligns with specific, contemporary preventive care guidelines. The 58-year-old's refusal of surgery contraindicates LDCT. The 42-year-old qualifies for the lowered mammography starting age (40 years). The 53-year-old qualifies for the lowered universal pneumococcal vaccination age (50 years). The 66-year-old's benign total hysterectomy is a definitive indication to cease cervical screening.

Step-by-Step Solution

1
Evaluate the 58-year-old man for lung cancer screening eligibility versus contraindications.
Omit LDCT screening.
USPSTF guidelines state that LDCT should be discontinued if a patient develops a life-limiting illness or explicitly refuses curative thoracic surgery.
2
Evaluate the 42-year-old woman for age-based cancer screenings.
Initiate screening mammography.
As of 2024, the USPSTF lowered the starting age for average-risk breast cancer screening from 50 to 40 years.
3
Evaluate the 53-year-old healthy man for adult vaccine eligibility.
Administer a pneumococcal conjugate vaccine.
ACIP recently lowered the age for universal pneumococcal vaccination for all adults from 65 to 50 years.
4
Evaluate the 66-year-old woman for continued cervical cancer screening post-hysterectomy.
Discontinue routine cervical cancer screening.
A total hysterectomy performed for a benign disease eliminates the cervix, negating the need for future Pap testing.

Key Concept

Application of current USPSTF and ACIP preventive screening and immunization guidelines, focusing on recent age threshold updates (mammography at 40, pneumococcal vaccine at 50) and clinical exclusions.
Question 4372Question →

During routine outpatient clinic visits, a physician encounters several patients with varying levels of readiness to modify their health behaviors. Based on the Transtheoretical Model of Change, match each patient statement to the most appropriate physician counseling strategy.

Click a left item, then click its matching right item

Items

"I feel perfectly fine. My blood pressure cannot be that high, and I do not want to take daily medication for a problem I cannot even feel."
"I know losing weight would help my osteoarthritis, but I am so tired after work. I am thinking about starting to exercise next month."
"I have decided to finally quit smoking. I bought the nicotine lozenges you suggested and picked this coming Monday as my quit day."
"I have been walking for 30 minutes every morning for the past 8 weeks and have not missed a single dose of my new diabetes medication."

Matches

Show answer & explanation

Answer

Precontemplation (no intent to change) matches with sharing objective data without arguing. Contemplation (ambivalent) matches with exploring ambivalence. Preparation (ready to change soon) matches with planning and anticipating triggers. Action (recently changed) matches with reinforcing success and relapse prevention.
Aligning the physician's counseling strategy with the patient's specific readiness to change (Transtheoretical Model) maximizes the likelihood of behavioral modification. Precontemplators require non-judgmental information and empathy to raise awareness. Contemplators require assistance in resolving ambivalence. Preparers need actionable, concrete plans and troubleshooting. Actors need positive reinforcement and structured relapse prevention.

Step-by-Step Solution

1
Evaluate the patient refusing blood pressure medication.
The patient is in the Precontemplation stage.
Identifying that the patient does not acknowledge a problem directs the physician to focus on raising awareness rather than forcing a treatment plan.
2
Evaluate the patient thinking about exercise for osteoarthritis.
The patient is in the Contemplation stage.
Recognizing the patient's awareness combined with ambivalence (weighing pros against the con of fatigue) indicates a need for motivational interviewing to tip the decisional balance.
3
Evaluate the patient who has set a quit date for smoking.
The patient is in the Preparation stage.
Because the patient is ready to act immediately, the physician must shift from building motivation to practical planning and addressing imminent barriers.
4
Evaluate the patient who has been exercising and taking medication for 8 weeks.
The patient is in the Action stage.
Since the behavioral change is recent (less than 6 months), the patient is at high risk for relapse; counseling must focus on reinforcing the new habits and anticipating high-risk situations.

Key Concept

Transtheoretical Model of Change (Stages of Change)
Question 4373Question →

A 4545-year-old man is brought to the emergency department after being found unresponsive in a garage. Beside him is a partially empty jug of antifreeze. Upon arrival, he is obtunded. His temperature is 37.0∘37.0^\circ C (98.6∘98.6^\circ F), blood pressure is 130/80130/80 mmHg, heart rate is 112112/min, and respiratory rate is 2424/min.

Laboratory studies are obtained and reveal the following:

TestResultReference Range
Serum sodium138138 mEq/L136−145136-145 mEq/L
Serum potassium4.54.5 mEq/L3.5−5.03.5-5.0 mEq/L
Serum chloride102102 mEq/L98−10698-106 mEq/L
Serum bicarbonate1212 mEq/L22−2822-28 mEq/L
Blood urea nitrogen (BUN)1414 mg/dL8−208-20 mg/dL
Serum creatinine1.51.5 mg/dL0.7−1.30.7-1.3 mg/dL
Serum glucose108108 mg/dL70−10070-100 mg/dL
Serum ethanolUndetectableUndetectable
Measured serum osmolality315315 mOsm/kg H2_2O275−295275-295 mOsm/kg H2_2O

Based on these findings, what is the patient's calculated osmolar gap?

Show answer & explanation

Answer: 28

Answer

28
The calculated serum osmolality is determined using the formula: 2×[Na+]+[BUN]/2.8+[Glucose]/182 \times [\text{Na}^+] + [\text{BUN}]/2.8 + [\text{Glucose}]/18. Plugging in the patient's values yields 2×138+14/2.8+108/18=276+5+6=287 mOsm/kg H2O2 \times 138 + 14/2.8 + 108/18 = 276 + 5 + 6 = 287 \text{ mOsm/kg H}_2\text{O}. The osmolar gap is the measured osmolality minus the calculated osmolality, which is 315−287=28 mOsm/kg H2O315 - 287 = 28 \text{ mOsm/kg H}_2\text{O}. An elevated osmolar gap (typically >10>10) alongside a high anion gap metabolic acidosis is a classic presentation for toxic alcohol poisoning, supported here by the presence of antifreeze (ethylene glycol).

Step-by-Step Solution

1
Calculate the expected serum osmolality using the standard physiological formula.
Calculated osmolality = 287 mOsm/kg H2O
This establishes the baseline osmoles contributed by the major plasma solutes (sodium, urea, and glucose).
2
Subtract the calculated osmolality from the measured osmolality.
315 - 287 = 28 mOsm/kg H2O
The difference between measured and calculated osmolality (osmolar gap) represents unmeasured osmotically active substances, such as toxic alcohols.

Key Concept

Interpreting Laboratory Results: Osmolar Gap Calculation
Estimated Time:1m 30s
Question 4374Question →

A general internist is reviewing the medical literature to update the clinic's management protocol for diabetic peripheral neuropathy. The physician reads a newly published randomized, placebo-controlled trial evaluating a novel oral analgesic. The study enrolled a total of 3030 patients (1515 in the treatment arm and 1515 in the placebo arm). The results demonstrate that patients receiving the novel analgesic experienced a mean reduction in pain scores of 4.54.5 points on a 1010-point visual analog scale, whereas the placebo group experienced a 1.21.2-point reduction. The reported p-value for this difference is 0.110.11. Based solely on this p-value, the physician decides not to incorporate the new medication into practice, concluding that the drug has been definitively proven to be no better than placebo. Which of the following best describes the primary statistical error in the physician's reasoning?

Show answer & explanation

Answer: Failing to recognize that the small sample size resulted in low statistical power and a high risk of a false-negative finding.

Answer

The physician failed to recognize that the small sample size resulted in low statistical power, leading to a high risk of a Type II error (a false-negative finding).
Statistical power is the probability of correctly rejecting the null hypothesis when a true difference exists (calculated as 1−β1 - \beta). Power is heavily dependent on sample size. In this scenario, the study has a very small sample size (n=30n=30 total), making it highly likely that it is underpowered to detect a statistically significant difference, even though a large, clinically meaningful effect was observed (4.54.5 vs 1.21.2 point reduction). When an underpowered study yields a non-significant p-value (p=0.11p=0.11), it simply indicates a failure to reject the null hypothesis; it does not prove that the null hypothesis is true. By concluding the drug is definitively ineffective based on this result, the physician is falling victim to a potential Type II error (a false negative).

Step-by-Step Solution

1
Analyze the reported results of the trial.
There is a large clinical difference between the groups (a 4.54.5-point reduction versus a 1.21.2-point reduction), but the p-value is 0.110.11, which is not statistically significant at the standard alpha of 0.050.05.
To identify a discrepancy between the clinical magnitude of the effect and the statistical significance.
2
Evaluate the study design parameters.
The sample size is extremely small, with only 1515 patients per group.
Sample size is the primary determinant of a study's statistical power.
3
Correlate the sample size with the statistical outcome.
A small sample size directly leads to low statistical power (typically 1−β1 - \beta).
Low power means the study lacks the ability to reliably detect a true difference, leading to a high risk of failing to reject a false null hypothesis (Type II error).
4
Critique the physician's conclusion.
The physician concluded the drug is 'definitively proven to be no better than placebo'.
A non-significant p-value in an underpowered study means 'absence of evidence', not 'evidence of absence'. The physician is committing a Type II error in their interpretation.

Key Concept

Hypothesis Testing and Statistical Power
Question 4375Question →

A clinical trial steering committee is finalizing the protocol for a phase III randomized controlled trial evaluating a novel biologic agent for moderate-to-severe plaque psoriasis. During the review, the committee discusses several potential modifications to the study design. Match each proposed trial modification with its most direct and primary impact on the statistical operating characteristics of the study.

Click a left item, then click its matching right item

Items

Decreasing the significance level (α\alpha) from 0.05 to 0.01
Expanding the number of study sites to increase total patient enrollment
Changing the primary endpoint from a continuous clinical score to a rare binary outcome
Implementing stricter inclusion criteria to create a highly homogenous patient cohort

Matches

Show answer & explanation

Answer

Decreasing alpha alters error risks, increasing sample size reduces standard error, changing to a rare binary endpoint causes power loss, and creating a homogenous cohort reduces population variance.
Each proposed study modification uniquely alters the mathematical components of hypothesis testing. Statistical power is determined by the chosen alpha level, sample size, effect size, and underlying variance. Understanding the specific mechanism of action for each modification is critical for optimizing trial design.

Step-by-Step Solution

1
Analyze how decreasing the significance level (α\alpha) affects error thresholds.
It results in a decreased Type I error and an increased Type II error.
α\alpha and β\beta (Type II error rate) are inversely related; a stricter threshold makes it harder to reject the null hypothesis.
2
Analyze the mathematical effect of increasing total patient enrollment (nn).
Increased nn reduces the standard error of the mean.
Standard error is calculated as the standard deviation divided by the square root of nn. Increasing the denominator shrinks the standard error, boosting power.
3
Compare continuous versus binary endpoints in terms of statistical efficiency.
Binary endpoints, particularly rare ones, yield less power than continuous endpoints.
Categorizing continuous data leads to information loss and requires larger sample sizes to detect equivalent effect sizes.
4
Analyze the effect of a homogenous cohort on statistical variance.
It reduces the population standard deviation (σ\sigma).
Patients with highly similar baseline characteristics have less variability in their measurements and responses, which tightens the data distribution and increases statistical power.

Key Concept

The relationship between study design parameters (sample size, variance, alpha threshold, endpoint data type) and statistical power/error rates.
Question 4376Question →

A 24-year-old nulligravid woman presents to the clinic for a well-woman evaluation. She has no significant past medical history and takes no daily medications. She is currently sexually active with a new male partner and uses oral contraceptive pills for pregnancy prevention. Her last Papanicolaou (Pap) test was performed at age 21, and the results were normal. The physician advises the patient that she is due for a repeat cervical cancer screening today. The patient politely declines, stating, "I received the complete series of HPV vaccines when I was in high school. I read that the vaccine prevents the virus that causes cervical cancer, so I shouldn't need to undergo these uncomfortable exams anymore." Which of the following is the most appropriate response by the physician?

Show answer & explanation

Answer: It is excellent that you received the vaccine, but it does not protect against every cancer-causing strain of the virus, making regular screening necessary.

Answer

The response that acknowledges the benefit of the vaccine but clarifies that it does not cover all cancer-causing strains, thereby requiring continued screening.
The correct response demonstrates effective patient counseling by first affirming a positive health behavior and then gently correcting a specific knowledge deficit. The human papillomavirus (HPV) vaccine is highly efficacious against the targeted high-risk strains (such as 16 and 18), but it does not cover all oncogenic strains. Therefore, standard USPSTF cervical cancer screening guidelines (cytology every 3 years for women aged 21-29) apply equally to vaccinated and unvaccinated individuals. Educating the patient on this specific limitation directly addresses her reason for refusal and allows for true informed consent.

Step-by-Step Solution

1
Analyze the patient's rationale for refusing the screening.
The patient believes that the human papillomavirus (HPV) vaccine provides 100% protection against cervical cancer, rendering screening obsolete.
Identifying the specific knowledge deficit is required to tailor the educational counseling response.
2
Recall the current preventive screening guidelines for cervical cancer.
USPSTF guidelines recommend cervical cancer screening every 3 years with cervical cytology alone for women aged 21 to 29 years, regardless of HPV vaccination status.
Physicians must apply the correct standard of care before negotiating the management plan with the patient.
3
Select the communication strategy that best corrects the misconception while maintaining the therapeutic alliance.
The best approach is to first validate the patient's proactive health measure (getting vaccinated) and then provide the medical fact that the vaccine does not cover all oncogenic strains.
Directly addressing the misconception respectfully empowers the patient to make a truly informed decision about her care.

Key Concept

Patient Counseling and Health Education regarding cervical cancer screening guidelines and HPV vaccine limitations.
Estimated Time:1m 0s
Question 4377Question →

Match each of the following sets of serum biochemical findings (calcium, phosphorus, and intact parathyroid hormone) with the diagnostic entity it most characteristically represents.

(Reference ranges: Serum calcium 8.4-10.2 mg/dL, Serum phosphorus 2.5-4.5 mg/dL, Intact PTH 15-65 pg/mL)

Click a left item, then click its matching right item

Items

Calcium 11.5 mg/dL, Phosphorus 2.2 mg/dL, Intact PTH 95 pg/mL
Calcium 12.8 mg/dL, Phosphorus 2.4 mg/dL, Intact PTH 5 pg/mL
Calcium 7.6 mg/dL, Phosphorus 5.8 mg/dL, Intact PTH 150 pg/mL
Calcium 8.1 mg/dL, Phosphorus 2.1 mg/dL, Intact PTH 135 pg/mL

Matches

Show answer & explanation

Answer

Profile 1 matches Primary hyperparathyroidism, Profile 2 matches Hypercalcemia of malignancy, Profile 3 matches Chronic kidney disease, and Profile 4 matches Vitamin D deficiency.
Each laboratory profile distinctly reflects the underlying pathophysiology of a specific calcium disorder. Primary hyperparathyroidism is characterized by autonomous PTH secretion leading to high calcium and low phosphorus. In hypercalcemia of malignancy, calcium is elevated via alternative pathways (like PTHrP or bone metastases), which strongly suppresses endogenous PTH. Chronic kidney disease results in phosphate retention and impaired calcitriol synthesis, causing low calcium, high phosphorus, and high PTH. Vitamin D deficiency results in poor intestinal absorption of both calcium and phosphorus; the subsequent secondary hyperparathyroidism normalizes or attempts to normalize calcium but further lowers phosphorus via renal wasting.

Step-by-Step Solution

1
Analyze the first laboratory profile.
Identified hypercalcemia coupled with elevated intact PTH and hypophosphatemia.
This pattern points to a primary overproduction of parathyroid hormone, as physiological PTH should be suppressed by hypercalcemia.
2
Analyze the second laboratory profile.
Identified severe hypercalcemia with appropriately suppressed intact PTH.
The suppressed PTH indicates a non-parathyroid source of hypercalcemia. The concurrent low phosphorus suggests a PTH-receptor agonist is at work, classically PTHrP seen in malignancy.
3
Analyze the third laboratory profile.
Identified hypocalcemia and hyperphosphatemia with elevated PTH.
The combination of elevated phosphorus and low calcium despite high PTH points to end-organ unresponsiveness and impaired filtration, which is the hallmark of chronic kidney disease.
4
Analyze the fourth laboratory profile.
Identified hypocalcemia and hypophosphatemia with elevated PTH.
The dual deficiency of calcium and phosphorus stems from a primary lack of gastrointestinal absorption, pointing directly to vitamin D deficiency. The elevated PTH reflects a secondary response.

Key Concept

Interpreting calcium, phosphorus, and parathyroid hormone levels together to differentiate the underlying etiologies of calcium homeostasis disorders.
Question 4378Question →

A cardiovascular research consortium is designing a randomized, placebo-controlled trial to evaluate a novel PCSK9 inhibitor for the prevention of major adverse cardiovascular events (MACE) in patients with stable coronary artery disease. The investigators initially calculate that enrolling 4,5004,500 patients followed for an average of 44 years will provide 80%80\% statistical power to detect a 20%20\% relative risk reduction in MACE, assuming a two-sided α\alpha of 0.050.05. The sample size calculation is based on an expected placebo event rate of 4%4\% per year. However, just before enrollment begins, a large epidemiological registry publishes data showing that due to widespread adoption of high-intensity statin therapy, the actual background rate of MACE in this specific population has decreased to 2%2\% per year. If the investigators proceed with the originally planned sample size and follow-up duration, which of the following is the most likely consequence for the trial?

Show answer & explanation

Answer: Increased probability of committing a Type II error

Answer

The trial will have an increased probability of committing a Type II error because the lower baseline event rate will result in fewer total endpoints, reducing the study's statistical power.
Statistical power is the probability of correctly rejecting the null hypothesis when a true effect exists (1−β1 - \beta). In event-driven trials, power is primarily determined by the total number of clinical endpoints that occur during the study. If the baseline incidence of the event is significantly lower than expected (2%2\% instead of 4%4\%), fewer total events will accrue over the same follow-up period. This reduction in events decreases the precision of the study (widening confidence intervals), thereby decreasing the statistical power. Because power is defined as 1−β1 - \beta, a decrease in power directly corresponds to an increase in β\beta, which is the probability of committing a Type II error (failing to detect a true difference).

Step-by-Step Solution

1
Analyze the change in the study population's baseline parameters.
The expected baseline event rate decreased from 4%4\% per year to 2%2\% per year.
Identifying altered baseline metrics is the first step in determining how a trial's mechanics will be affected.
2
Determine the effect of this change on the total accrued events.
With a fixed sample size (4,5004,500) and follow-up duration (44 years), a halving of the event rate yields significantly fewer total MACE endpoints.
In time-to-event or binary outcome trials, statistical power is driven primarily by the number of events, not just the number of enrolled patients.
3
Identify the impact on statistical precision and power.
Fewer events lead to wider confidence intervals and decreased statistical power.
Less data (fewer events) means the study has less ability to confidently distinguish a true treatment effect from random variation.
4
Relate the change in statistical power to the specific error types.
Decreased statistical power (1−β1-\beta) directly corresponds to an increased β\beta, which is the Type II error rate.
Type II error is the probability of failing to detect a true difference; as power drops, this risk inherently rises.

Key Concept

In clinical trials, statistical power (1−β1-\beta) depends on the total number of accrued events. A lower-than-expected baseline event rate yields fewer events, which decreases power and increases the probability of committing a Type II error (β\beta).
Question 4379Question →

A 54-year-old man comes to the clinic for a routine follow-up. He has a history of type 2 diabetes mellitus and familial combined hyperlipidemia. He admits to poor medication adherence over the last year and has not taken his prescribed rosuvastatin or metformin for several months. He has no current symptoms. Vital signs are within normal limits. Physical examination reveals small, yellowish papules on the extensor surfaces of his arms and shoulders. Laboratory studies show the following:

Laboratory TestResult
Sodium125 mEq/L125\text{ mEq/L}
Potassium4.1 mEq/L4.1\text{ mEq/L}
Chloride94 mEq/L94\text{ mEq/L}
Bicarbonate25 mEq/L25\text{ mEq/L}
Blood urea nitrogen12 mg/dL12\text{ mg/dL}
Creatinine0.8 mg/dL0.8\text{ mg/dL}
Glucose150 mg/dL150\text{ mg/dL}

A serum osmolality is subsequently measured and reported as 289 mOsm/kg H2O289\text{ mOsm/kg H}_2\text{O} (reference range: 275−295 mOsm/kg H2O275-295\text{ mOsm/kg H}_2\text{O}). Which of the following is the most likely underlying mechanism for this patient's hyponatremia?

Show answer & explanation

Answer: Laboratory measurement artifact due to a decreased plasma water fraction

Answer

Laboratory measurement artifact due to a decreased plasma water fraction
The correct underlying mechanism is a laboratory measurement artifact due to a decreased plasma water fraction. This patient has a significantly low serum sodium level (125 mEq/L125\text{ mEq/L}) but a normal measured serum osmolality (289 mOsm/kg H2O289\text{ mOsm/kg H}_2\text{O}). This combination defines isotonic hyponatremia, also known as pseudohyponatremia. The patient's clinical history of familial combined hyperlipidemia, recent medication nonadherence, and the presence of eruptive xanthomas (yellowish papules on the extensor surfaces) strongly point to severe hypertriglyceridemia. In states of marked hyperlipidemia or paraproteinemia (such as multiple myeloma), large lipid or protein molecules occupy an unusually large volume of the total plasma. This decreases the fraction of plasma that is composed of water. When clinical laboratories use indirect ion-selective electrode (ISE) methods, the sample is first diluted, and the sodium concentration is calculated based on the total plasma volume rather than the physiologically relevant plasma water volume. This results in a falsely low reported sodium concentration, despite the actual sodium concentration in the plasma water—and thus the patient's true tonicity—remaining completely normal.

Step-by-Step Solution

1
Interpret the basic metabolic panel.
The patient has marked hyponatremia with a serum sodium level of 125 mEq/L125\text{ mEq/L}.
Identifying the primary electrolyte abnormality directs the subsequent diagnostic workup.
2
Correlate the hyponatremia with the measured serum osmolality.
The measured serum osmolality is 289 mOsm/kg H2O289\text{ mOsm/kg H}_2\text{O}, which is within the normal reference range, indicating isotonic hyponatremia.
Hyponatremia must be classified by tonicity (isotonic, hypotonic, hypertonic) to determine the underlying etiology.
3
Connect the clinical presentation to the laboratory classification.
The patient has a history of familial combined hyperlipidemia, medication nonadherence, and eruptive xanthomas (indicative of severe hypertriglyceridemia). This confirms a diagnosis of pseudohyponatremia.
Severe hyperlipidemia is a classic cause of isotonic hyponatremia (pseudohyponatremia) due to a laboratory measurement artifact.

Key Concept

The initial step in interpreting hyponatremia is evaluating serum osmolality; isotonic hyponatremia (pseudohyponatremia) is a laboratory artifact caused by a decreased plasma water fraction in the setting of severe hypertriglyceridemia or paraproteinemia.
Estimated Time:1m 30s
Question 4380Question →

A 42-year-old man with a history of poorly controlled hypertension and a recent transient ischemic attack presents to the clinic for a follow-up examination. During the encounter, the physician notes a strong odor of tobacco smoke on the patient's clothing. The physician plans to implement a structured, guideline-concordant tobacco cessation intervention. According to the United States Preventive Services Task Force (USPSTF) recommended framework for counseling, arrange the following physician actions in the correct sequential order from first to last.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence follows the 5 A's framework: Ask about use, Advise to quit, Assess readiness, Assist with the quit attempt, and Arrange follow-up.
The correct sequence precisely reflects the evidence-based USPSTF 5 A's behavioral counseling framework for tobacco cessation. The physician must first 'Ask' to identify the tobacco user. Next, the physician must 'Advise' the patient to quit using clear, personalized messaging (e.g., linking it to the recent TIA). Following the advice, the physician must 'Assess' if the patient is ready to make a quit attempt. If the patient is ready, the physician then provides 'Assist'ance through counseling and medications. Finally, the physician must 'Arrange' follow-up to provide ongoing support and prevent relapse.

Step-by-Step Solution

1
Identify the clinical framework being tested based on the scenario.
The scenario requires the application of the USPSTF 5 A's framework for tobacco cessation counseling.
The 5 A's model is the standard, evidence-based approach for addressing tobacco dependence in clinical practice.
2
Map the specific clinical actions provided in the items to the components of the 5 A's framework.
Inquiring = Ask; Recommending = Advise; Determining willingness = Assess; Discussing pharmacotherapy = Assist; Scheduling follow-up = Arrange.
Accurately identifying the clinical translation of each theoretical component is essential for establishing the correct order.
3
Arrange the identified actions in the correct chronological sequence.
The correct chronological sequence is to first Inquire, then Recommend, then Determine willingness, then Discuss options, and finally Schedule follow-up.
The framework is designed to flow chronologically; a physician cannot effectively assist a patient who has not yet been assessed for readiness, nor can they assess readiness before clearly advising the patient to quit.

Key Concept

The USPSTF 5 A's Framework for Smoking Cessation Counseling
PreviousPage 219 / 237Next